Spironolactone for COVID-19
Spironolactone has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Integrative analysis of viral entry networks and clinical outcomes identifies a protective role for spironolactone in severe COVID-19, medRxiv, doi:10.1101/2022.07.02.22277181 ,
A computational approach to drug repurposing using graph neural networks, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105992 ,
A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2 ,
Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156 ,
Improved And Optimized Drug Repurposing For The SARS-CoV-2 Pandemic, bioRxiv, doi:10.1101/2022.03.24.485618 ,
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870 ,
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.